<div id="readability-page-1"><h3>End of Quarter Sale - 50% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an announcement. Shanghai Junshi Biosciences has disclosed that its chairman, controlling shareholder and actual controller, Xiong Jun, has completed a planned increase in his holdings of both A shares and H shares of the company. The plan, launched on 12 April 2025, aimed to invest at least RMB100 million in additional shares, with at least RMB50 million in A shares, through exchanges in Shanghai and Hong Kong. From 12 April 2025 to 31 March 2026, Xiong Jun purchased a total of 3,259,495 A and H shares, representing about 0.32% of the company’s total share capital. The total transaction value reached RMB100.64 million, slightly above the minimum commitment, signaling management’s confidence in the company and resulting in his equity holding crossing the 1% disclosure threshold, a development of note for investors monitoring ownership concentration and governance dynamics. The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page. More about Shanghai Junshi Biosciences Co., Ltd. Class H Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong, focused on the research, development and commercialization of innovative therapies. The company operates through A shares on the Shanghai Stock Exchange and H shares on the Stock Exchange of Hong Kong, targeting domestic and international capital markets for its growth and financing needs. Average Trading Volume: 3,356,361 Technical Sentiment Signal: Sell Current Market Cap: HK$35.64B For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.</div>

512290

159615

516930

Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Xiong Jun, has completed a planned shareholding increase, investing over RMB100 million in A and H shares. This acquisition, which took place from April 12, 2025, to March 31, 2026, involved purchasing 3,259,495 shares, representing approximately 0.32% of the company's total share capital. This move indicates management's confidence in the company, with Xiong's equity holding surpassing the 1% disclosure threshold. The current analyst rating for the stock is a Hold with a price target of HK$22.50.

Tip Ranks

Guotai CSI Bio-medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

JUNSHI BIO

Yinhua CSI Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Junshi Biosciences

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase